Predict your next investment

Redesign Science company logo
HEALTHCARE | Drug Discovery

See what CB Insights has to offer

Founded Year



Seed VC - II | Alive

Total Raised


Last Raised

$5M | 2 mos ago

About Redesign Science

Redesign Science is a computational chemistry company that engages in early-stage, small molecule drug discovery. The company efficiently simulates protein targets at the atomic level to reveal hidden, subtle drug opportunities that fall outside the capability and scope of alternative computational models.

Redesign Science Headquarter Location

180 Varick Street Floor 6

New York, New York, 10014,

United States

Latest Redesign Science News

Redesign Science and OpenEye Scientific announce strategic partnership

Jan 7, 2020

Partnership will advance both firms' positions in the field of molecular dynamics-based drug discovery News provided by Share this article NEW YORK and SANTA FE, N.M., Jan. 7, 2020 /PRNewswire/ -- Redesign Science and OpenEye Scientific are pleased to announce that they have entered into a strategic partnership to integrate OpenEye's pioneering Orion computational platform into Redesign's drug discovery platform. The practice of drug discovery has radically transformed in recent decades as advances in computational power and simulation methods have thrown open the doors to "rational" drug discovery, which focuses on discovering new pharmaceuticals through an intentional, first-principles approach that contrasts with the trial-and-error approaches favored by previous generations. OpenEye is a recognized leader in the field of cheminformatics software for drug discovery, providing a reliable API customers use to build highly customizable programs and workflows. Its newly released Orion computational platform, built on AWS, extends this capability by serving as a highly scalable cloud-based computational analysis system, bringing together all of OpenEye's previously developed tools in a single, customizable and massively scalable interface. Redesign Science will integrate these tools into its own molecular dynamics platform, allowing it to scale its drug discovery efforts more rapidly. According to Redesign cofounder and CTO Haotian Li: "At Redesign, we develop highly customized workflows for each project, and leveraging Orion brings reproducibility, flexibility, and speed to key parts of our development process as we deploy these workflows on the cloud. This technology means we can scale up our business without having to scale up human costs and development times at the same rate - it is a major key to Redesign's growth." OpenEye sees not just economic benefit but also strategic rationale in this partnership and took an equity stake in Redesign during its recently-closed seed investment round. "OpenEye is committed to advancing rational drug discovery by providing an evolving platform of state-of-the-art methods for pharmaceutical development and analysis. We are excited by Redesign's vision and how we might help them achieve their goals. We see cloud computing as central to the future of our industry, and investing in Redesign is a part of our broader strategy of engagement with dynamic, revolutionary enterprises," says OpenEye CEO, Anthony Nicholls. Redesign is currently advancing drug discovery programs with multiple biotech partners through the integration of the Orion platform with its existing molecular dynamics and virtual screening technologies. About Redesign Science - Founded in 2017, Redesign Science is focused on delivering novel chemical matter to biotech partners. Redesign's mission is to develop and optimize new therapeutics for novel or poorly understood targets, and to drastically reduce its partners' time investment in early-stage drug discovery. About OpenEye Scientific – OpenEye has built a reputation as a scientific leader in the field of molecular design based on two decades of delivering useful applications and programming toolkits. Our scientific approach has focused on the power of molecular 3D structure to inform and guide, in particular via the concept of shape similarity. We have changed industry perception of what is possible with the speed, robustness and scalability of our tools and have recently built these into a ground-up, cloud-native platform, Orion. Combining unlimited computation and storage with powerful tools for data sharing, visualization and analysis in an open development platform, Orion offers unprecedented capabilities for drug discovery and optimization. OpenEye Scientific is a privately held company headquartered in Santa Fe, New Mexico, with offices in Boston, Massachusetts, Cologne, Germany, Strasbourg, France and Tokyo, Japan. For further information on the company and its products, see . Media contacts -

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Redesign Science

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Redesign Science is included in 2 Expert Collections, including Biopharmaceuticals.



5,732 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.


Artificial Intelligence

7,364 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

Redesign Science Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Redesign Science Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.